Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-11-28
2006-11-28
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S325000, C435S455000
Reexamination Certificate
active
07141240
ABSTRACT:
Disclosed herein are cells that secrete insulin in a glucose-dependent manner. The cell line comprises insulin-secreting cells that have been transfected with a minigene construct comprising a nucleotide sequence encoding for glucagon-like peptide-1 (GLP-1). In preferred embodiments, the minigene construct is operatively associated with a promoter. The cell line may be used to treat diabetes or other conditions in which delivering insulin in a glucose-dependent manner would be advantageous, to investigate the function and development of pancreatic cells, and to test the efficacy of drugs that stimulate insulin secretion. The cells may be implanted in a mammal, or may be included in a device that resides exterior to the mammal, yet which delivers insulin to the mammal in response to the glucose level of a body fluid in contact therewith. The minigene construct may also be implemented in conjunction with an in vivo gene transfer approach.
REFERENCES:
patent: 4935000 (1990-06-01), Dudek
patent: 5120712 (1992-06-01), Habener
patent: 5219752 (1993-06-01), Takazawa et al.
patent: 5397706 (1995-03-01), Correa et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5530023 (1996-06-01), Korth
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5574008 (1996-11-01), Johnson et al.
patent: 5587309 (1996-12-01), Rubin et al.
patent: 5595722 (1997-01-01), Grainger et al.
patent: 5614492 (1997-03-01), Habener
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5654267 (1997-08-01), Vuori et al.
patent: 5665864 (1997-09-01), Quaranta et al.
patent: 5670360 (1997-09-01), Thorens
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5723333 (1998-03-01), Levine et al.
patent: 5744327 (1998-04-01), Newgard
patent: 5747325 (1998-05-01), Newgard
patent: 5773255 (1998-06-01), Laurance et al.
patent: 5792656 (1998-08-01), Newgard
patent: 5804421 (1998-09-01), Vinik et al.
patent: 5811266 (1998-09-01), Newgard
patent: 5837236 (1998-11-01), Dinsmore
patent: 5840531 (1998-11-01), Vinik et al.
patent: 5846747 (1998-12-01), Thorens et al.
patent: 5846937 (1998-12-01), Drucker
patent: 5849493 (1998-12-01), Montminy et al.
patent: 5854292 (1998-12-01), Ailhaud et al.
patent: 5858973 (1999-01-01), Habener et al.
patent: 5861278 (1999-01-01), Wong et al.
patent: 5863555 (1999-01-01), Heiber et al.
patent: 5880261 (1999-03-01), Waeber et al.
patent: 5888705 (1999-03-01), Rubin et al.
patent: 5895785 (1999-04-01), Korth
patent: 5902577 (1999-05-01), Asfari et al.
patent: 5928942 (1999-07-01), Brothers
patent: 5948623 (1999-09-01), Sosa-Pineda et al.
patent: 5958909 (1999-09-01), Habener
patent: 5961972 (1999-10-01), Dinsmore
patent: 5977071 (1999-11-01), Galloway et al.
patent: 5981488 (1999-11-01), Hoffmann
patent: 5993799 (1999-11-01), Newgard
patent: 5994127 (1999-11-01), Selden et al.
patent: 6001647 (1999-12-01), Peck et al.
patent: 6004775 (1999-12-01), Shimasaki et al.
patent: 6006753 (1999-12-01), Efendic
patent: 6048724 (2000-04-01), Selden et al.
patent: 6051689 (2000-04-01), Thorens
patent: 6071697 (2000-06-01), Sosa-Pineda et al.
patent: 6087129 (2000-07-01), Newgard et al.
patent: 6110707 (2000-08-01), Newgard et al.
patent: 6110743 (2000-08-01), Levine et al.
patent: 6114599 (2000-09-01), Efrat
patent: 6127598 (2000-10-01), German et al.
patent: 6132708 (2000-10-01), Grompe
patent: 6133235 (2000-10-01), Galloway et al.
patent: 6153432 (2000-11-01), Halvorsen et al.
patent: 6156306 (2000-12-01), Brownlee et al.
patent: 6160022 (2000-12-01), Bergeron, Jr.
patent: 6162907 (2000-12-01), Habener
patent: 6210960 (2001-04-01), Habener et al.
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6642003 (2003-11-01), Perfetti
patent: 2004/0002468 (2004-01-01), Wadsworth et al.
patent: 01/39784 (2001-06-01), None
U.S. Appl. No. 60/310,982.
Hanahan, Nature, 315:115-122, 1985.
Mountain, Trends Biotechnol, 18:119-128, 2000.
Merriam-Webster's collegiate dictionary, 10thed., Springfield, Massachusetts, USA, 2001, p. 41.
Invitrogen life technologies, Catalog No. V900-20, 2001 [online], [retrieved from the Invitrogen website using internet <URL: http://www.invitrogen.com/content/sfs/manuals/psectag2—man.pdf>.
Hongxiang Hui et al., “Glucagon-Like Peptide 1 Induces Differentiation of Islet Duodenal Homeobox-1—Positive Pancreatic Ductal Cells Into Insulin-Secreting Cells,”Diabetes, vol. 50, pp. 785-796 (Apr. 2001).
R. Ritzel et al., “Glucagon-Like Peptide 1 Increases SEcretory Burst Mass of Pulsatile Insulin Secretion in Patients with Type 2 Diabetes and Impaired Glucose Tolerance,”Diabetes, vol. 50, pp. 776-784 (Apr. 2001).
Xiaolin Wang et al., “Glucagon-like peptide-1 Regulates the Beta Cell Transcription Factor, PDX-1, in Insulinoma cells,”Endocrinology, vol. 140, No. 10, pp. 4904-4907 (1999).
A. Vinik et al., “Induction of Pancreatic Islet Neogenesis,”Hormone and Metabolic Research, vol. 29, No. 6, pp. 255-322 (Jun. 1997).
KM Narayan et al., “Translation research for chronic disease: the case of diabetes: the case of diabetes,”Diabetes Care, 23-1794-1978 (2000).
DJ Ducker, “The glucagon-like peptides,”Endocrinology, 142:521-527 (2001).
B. Thorens and G. Waeber, “Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM,”Diabetes, 42:1219-1225 (1993).
MA Nauck et al., “Influence of glucagon-like peptide 1 on fasting glycemia in type 1 diabetic patients treated with insulin after sulfonylurea secondary failure,”Diabetes Care, 21:1925-1931 (1998).
SY Shieh and MJ Tsai, “Cell-specific and ubiquitous factors are responsible for the enhancer activity of the rate insulin II gene,”J Biol Chem, 266:16708-16714 (1991).
X. Wang et al., “Glucagon-like peptide-1 regulates the beta cell transcription factor, PDS-1, in insulinoma cells,”Endocrinology, 140:4904-4907 (1999).
R. Perfetti and P. Merkel, “Glucagon-like peptide-1: a major regulator of pancreatic β-cell function,”European J Endocrinol, 143:717-725 (2000).
A. Vinik et al., “Induciton of pancreatic islet neogenesis,”Horm Metab Res(Symposium Report), 29:278-293 (1997).
MA Nauck et al., “Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1 [7-36 amide] in type 2 (non-insulin dependent) diabetic patients,”Diabetologia, 36:741-744 (1993).
C. Orsakov, “Glucagon-like peptide-1, a new hormone of the enteroinsular axis,”Diabetologia, 35:701-711 (1992).
JJ Holst, “Glucagon-like peptide-1 (GLP-1) a newly discovered GI hormone,”Gastroenterology, 107:1848-1855 (1994).
MA Hussain and JF Habaner, “Glucagon-like peptide-1 increases glucose-dependent activity of the homeoprotein IDX-1 transactivating domain in pancreatic beta-cells,”Biochemical&Biophysical Research Communications, 274:616-619 (2000).
CA Leech et al., “Expression of cAMP-regulated guanine nucleotide exchange factors in pancreati beta-cells,”Biochemical&Biophysical Research Communication, 278:44-47.
J. Buteau et al., “Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodental homebox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells,”Diabetologia, 42:856-864 (1999).
DA Stoffers et al., “Homeodomain protein IDX-1: A master regulator of pancreas development and insulin gene expression,”Trends Endocrinology Metab, 8:145:151 (1997).
A: Wilmen et al., “The genomic organization of the human GLP-1 receptor gene,”Exp Clin Endocrinol Diabetes, 106:299-302 (1998).
G. Teitelman et al., “Cell lineage analysis of pancreatic islet cell development; glucagon and insulin cells arise from catecholaminergic precursor present in the pancreatic duct,”Dev Biol, 121:454-466 (1987).
R. L. Pictet et al., “An ultrastructural analysis of the developing embryonic pancreas,”Dev Biol, 29:436-467 (1972).
J. Jonsson et al., “Insulin-promotor fa
Hui Hongxiang
Perfetti Riccardo
Cedars-Sinai Medical Center
Davis , Wright, Tremaine, LLP
Levy Seth D.
Whiteman Brian
LandOfFree
Glucose-dependent insulin-secreting cells transfected with a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucose-dependent insulin-secreting cells transfected with a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucose-dependent insulin-secreting cells transfected with a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3679932